Drug Detail

Information about INBRX-109

Generic Name
IND
INBRX-109
Brand Name (US)
Manufacturer
Inhibrx, Inc.
Drug Type
DR5 agonist
Delivery
Intravenous
Approval Status
Phase 2
Indications
Overall Strategy
GIST cell based
Strategy
Activate Death Receptor
Drug Category
SDH-directed

The FDA has granted an orphan drug designation to INBRX-109 for the treatment of chondrosarcoma, according to a press release by Inhibrx, Inc.1

INBRX-109 is a tetravalent death receptor 5 (DR5) agonist antibody that is meant to leverage tumor-biased cell death caused by DR5 activation.and avoid apoptosis of normal cells.


Links

 

INBRX Pipeline page
   

Trials of this drug


Trial results


Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed